Focusrite’s trading statement indicates constant currency sales growth of over 25%, even better sales growth than the headline 19%, because of the US dollar’s depreciation. The background is a continuation of widespread demand for the full product range across all the main geographies. Although trading patterns may be shifting to the first half, we are upgrading our forecasts by c 5%.
Written by
Focusrite |
Rising scale |
Interim pre-close statement |
Consumer Electronics |
9 March 2018 |
Share price performance
Business description
Next events
Analysts
Focusrite is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||
Focusrite’s trading statement indicates constant currency sales growth of over 25%, even better sales growth than the headline 19%, because of the US dollar’s depreciation. The background is a continuation of widespread demand for the full product range across all the main geographies. Although trading patterns may be shifting to the first half, we are upgrading our forecasts by c 5%.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
EV/EBITDA |
Yield |
8/16 |
54.3 |
7.7 |
11.8 |
2.0 |
30.1 |
19.6 |
0.5 |
8/17 |
66.1 |
9.5 |
14.8 |
2.7 |
24.0 |
14.6 |
0.8 |
8/18e |
74.6 |
10.4 |
15.9 |
3.0 |
22.3 |
13.2 |
0.8 |
8/19e |
79.9 |
11.1 |
16.8 |
3.3 |
21.2 |
12.5 |
0.9 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Strong Christmas drives positive half year trading Focusrite has released a very encouraging pre-close half-year trading statement. Revenue, cash and profits have all grown y-o-y, the latter implying costs are not expected to be out of line. Trends seen in FY17 have continued, with growth spread across product groups and in all major geographies. Strong sales had a “particularly strong boost” through increased demand over the Christmas holiday period, which may signal a wider consumer appreciation of the products, with a sign of a change in the phasing of revenue. End February 2018 net cash was £19.7m, up from £14.2m at end August 2017.
Underlying sales exceed headline growth
Guidance of H118 revenue of at least £38m implies growth of 19% y-o-y. This is spread across all regions and sales in US$ regions, amounting to around 60% of revenue, led growth in FY17. Given that the US$ has depreciated by c 8% y-o-y, underlying sales growth has been even stronger, at over 25%.
Underlying upgrade of 5%
We upgrade our FY18e EBITDA by 5.3% and PBT by 3.7%. The latter is lower because we believe the relative strength of sterling in H1 will bring some currency losses on the translation of US$ cash. For FY19e, we upgrade PBT by 5% and EBITDA by 3.9%. We now forecast year-end net cash of £20.4m (previously £17.6m) carrying forward the H1 advance.
Valuation: 379-400p
Our DCF valuation is 379p/share, which would put the shares on an FY18e P/E of 23.8x and EV/EBITDA of 14.1x. A comparison against peers, taking into account £20m of excess cash, suggests a somewhat higher level of 400p.
Positive half year trading: Strong Christmas
Focusrite has released a very encouraging pre-close half-year trading statement which, though brief, bears some analysis.
Revenue, profits and cash have all grown compared with the first half of the last financial year. The extent to which profit as well as revenue and cash have grown will not be confirmed until results are released. However, we take this to mean that costs are not expected to be out of line.
We understand that trends seen in FY17 have broadly continued. Those were, firstly, growth in all geographies, but led by the US and Rest of World (mainly Asia), and secondly growth in both divisions, led by Novation. Focusrite continues to build its leading international positions in its specialised markets of audio interfaces and sound generation.
It is reassuring that growth has also been widely spread across product groups and that both the Scarlett and Launchpad ranges have grown strongly. Accelerating growth in the Novation group was one of the positive features of FY17, so that it increased its share of total revenue from 25% in FY16 to 29% in FY17.
Strong sales had a “particularly strong boost” with increased demand over the Christmas holiday period, and management raises the idea that this may signal a wider consumer appreciation of the products, with a sign of a change in the phasing of revenue. The trend has been towards high profile products, such as the Novation’s Launchpad, being selected as Christmas presents. This may have been helped by their availability more widely, for example on Amazon, rather than the previous concentration in specialist music dealerships.
Forecasts: Underlying upgrade of 5%
We upgrade our forecasts in line with guidance of H118 revenue of over £38m, up 19% y-o-y, as well as end February 2018 net cash of £19.7m, up from £14.2m at end August 2017. We estimate that the strengthening of the US$ against sterling from an average rate of 1.26 in H117 to c 1.38 in H118 will have meant an 8% depreciation in the sterling value of US$ sales making up c 60% of total revenue, so that underlying constant currency growth, at over 25%, was even stronger than the headline 19%. However, the natural hedge that the company enjoys against the US$ means that there should be no material effect on margin.
Exhibit 1: Changes to forecasts
£m |
FY18e old |
FY18e new |
% |
FY19e |
FY19e new |
% |
FY20 |
FY20e new |
% |
Revenues |
72.7 |
74.6 |
2.5% |
78.6 |
79.9 |
1.7% |
84.9 |
85.9 |
1.2% |
Gross profit |
30.3 |
31.0 |
2.6% |
32.7 |
33.3 |
1.8% |
35.3 |
35.9 |
1.6% |
Gross margin |
41.6% |
41.6% |
0.0% |
41.6% |
41.6% |
0.0% |
41.6% |
41.7% |
0.1% |
Adjusted EBITDA |
13.8 |
14.6 |
5.3% |
14.8 |
15.4 |
3.8% |
15.6 |
16.2 |
3.9% |
Adjusted EBITDA margin |
19.0% |
19.5% |
0.5% |
18.8% |
19.2% |
0.4% |
18.4% |
18.9% |
0.5% |
Normalised operating profit |
10.0 |
10.7 |
7.1% |
10.5 |
11.1 |
5.3% |
11.0 |
11.6 |
4.9% |
Normalised PBT |
10.0 |
10.4 |
3.7% |
10.6 |
11.1 |
5.3% |
11.1 |
11.6 |
4.8% |
Normalised EPS (p) |
15.3 |
15.9 |
3.7% |
15.9 |
16.8 |
5.3% |
16.4 |
17.2 |
4.8% |
Net cash |
17.6 |
20.4 |
15.5% |
20.6 |
23.5 |
14.2% |
24.3 |
27.4 |
12.6% |
Source: Edison Investment Research
We are cautious in our forecast for the second half, as a result of the possibility that trading patterns may have changed, giving a seasonal boost to Christmas. Our H2 revenue forecast now only represents 7.5% y-o-y growth which on the face of it looks cautious. On the other hand, it represents a 51:49 split of sales between H1 and H2, against a 48.5:51.5 split in FY17.
Cash forecast – at least £20m
The £5.5m increase in net cash compared with August 2017 implies a further improvement in our previous FY18 full year net cash flow forecast of £3.4m. We now forecast £20.4m net cash at end August 2018. In part, this represents the £0.6m improvement in our forecast EBITDA. More importantly, it reflects efficient utilisation of working capital, particularly inventory, which we now expect to turn 4.9x, close to FY17’s level of 4.8x, which we had treated as temporarily low. Given that year end has in the past seen a higher cash balance than H1, we would not be surprised to see this level exceeded.
Valuation: 379-400p
Focusrite is market leader in its specialist technical field. Its rating is dependent on the market’s confidence in its ability to remain at the forefront of a competitive field of technical developments and to service a demanding user group. The company is showing an ability to sustain this reputation and for this reason we use a DCF projection to place a value on the longer-term income stream available to investors.
DCF valuation of 379p
We make no change to our DCF projection which extends our forecasts out to 10 years on growth fading in the last three years to a terminal rate of 2%. We assume a terminal EBITDA margin of 21% (2017 actual: 19.8%) and capex investment (including R&D) at 7% of revenue, reducing to 5% in the terminal period. We assume an equity-only cost of capital of 8.4% (risk-free rate 3%, risk premium 6%, beta 0.9), resulting in a valuation of 379p/share (of which 234p is in the terminal value). That would put the shares on an FY18 P/E of 23.8x and EV/EBITDA of 14.1x.
Peer group comparison: 400p
As there is no close small-cap peer, we define the relevant group as UK smaller-cap tech, electronics and consumer companies in relevant subsectors, as well as relevant companies in US and European markets. This is far from an exact comparison, but does give some context in terms of market valuations in adjacent sectors.
Exhibit 2: Peer valuation
All calendarised to August |
Country |
Mid-price |
Mkt cap |
Mkt cap |
P/E (x) |
P/E (x) |
EV/EBITDA |
EV/EBITDA |
Universal Electronics |
US |
52.7 |
742 |
570 |
15.4 |
12.8 |
8.9 |
7.6 |
Tivo |
US |
15.0 |
1836 |
2160 |
9.1 |
7.5 |
9.5 |
8.5 |
Morgan Adv. Materials |
UK |
326.6 |
933 |
920 |
13.4 |
12.6 |
5.6 |
5.3 |
Photo-Me International |
UK |
178.4 |
672 |
672 |
18.2 |
17.0 |
6.1 |
5.7 |
Oxford Instruments |
UK |
765.0 |
439 |
561 |
14.4 |
13.4 |
7.9 |
7.6 |
Bang & Olufsen |
DK |
168.2 |
7275 |
871 |
134.7 |
29.6 |
101.5 |
75.6 |
XP Power |
UK |
3390.0 |
644 |
655 |
20.0 |
18.9 |
10.5 |
10.0 |
Avid Technology |
US |
5.1 |
210 |
162 |
15.3 |
6.8 |
7.7 |
N/A |
Gooch & Housego |
UK |
1382.5 |
340 |
337 |
24.7 |
23.4 |
10.0 |
9.5 |
Dialight |
UK |
537.0 |
176 |
212 |
17.8 |
12.7 |
6.5 |
5.0 |
Quixant |
UK |
387.5 |
256 |
276 |
24.1 |
21.1 |
12.4 |
10.6 |
Judges Scientific |
UK |
2160.0 |
133 |
119 |
17.0 |
16.2 |
8.4 |
7.5 |
B&C Speakers |
IT |
11.8 |
129 |
112 |
18.1 |
17.3 |
10.3 |
9.4 |
Trakm8 Holdings |
UK |
96.0 |
34 |
54 |
13.3 |
9.6 |
5.6 |
4.6 |
Gear 4 Music (Hldgs) |
UK |
639.0 |
133 |
153 |
81.9 |
52.8 |
25.7 |
18.7 |
Average |
29.2 |
18.1 |
15.8 |
13.3 |
||||
Focusrite |
UK |
360 |
209 |
22.6 |
21.5 |
13.4 |
12.7 |
|
Premium/(discount) |
-22.4% |
18.6% |
-15.1% |
-4.3% |
Source: Bloomberg. Note: LSE subsectors: Electrical Components & Equipment, Computer Hardware, Recreational Products; Retail: relevant audio/video companies from US and European markets. Market cap £25m-2bn. Outliers excluded from table. Prices as at 8 March 2018. N/A: data not available.
Focusrite trades at an average FY18e 22.4% discount and FY19e 18.6% P/E premium to the group. On an EV/EBITDA basis it trades at an FY18e 15.1% and an FY19e 4.3% discount to the group. However, we note the now significant excess cash of £19.7m, for which the P/E measure gives no credit (the EV/EBITDA valuation does). Adjusting to average peer multiples and allowing for that cash in the P/E comparison values Focusrite shares at 418p on a P/E basis and 382p on an EV/EBITDA basis, a blend of 400p, somewhat above our DCF valuation.
Exhibit 3: Financial summary
£'000s |
2016 |
2017 |
2018e |
2019e |
2020e |
||
31-August |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
INCOME STATEMENT |
|||||||
Revenue |
|
|
54,301 |
66,055 |
74,552 |
79,890 |
85,882 |
Cost of Sales |
(33,439) |
(39,704) |
(43,503) |
(46,618) |
(50,028) |
||
Gross Profit |
20,862 |
26,351 |
31,049 |
33,272 |
35,853 |
||
EBITDA |
|
|
10,249 |
13,109 |
14,563 |
15,360 |
16,239 |
Operating profit (before amort. and except). |
|
7,677 |
9,470 |
10,674 |
11,072 |
11,573 |
|
Amortisation of acquired intangibles |
0 |
0 |
0 |
0 |
0 |
||
Exceptionals |
(537) |
0 |
0 |
0 |
0 |
||
Share-based payments |
0 |
0 |
0 |
0 |
0 |
||
Reported operating profit |
7,140 |
9,470 |
10,674 |
11,072 |
11,573 |
||
Net Interest |
(14) |
42 |
(300) |
50 |
50 |
||
Joint ventures & associates (post tax) |
0 |
0 |
0 |
0 |
0 |
||
Exceptionals |
0 |
0 |
0 |
0 |
0 |
||
Profit Before Tax (norm) |
|
|
7,663 |
9,512 |
10,374 |
11,122 |
11,623 |
Profit Before Tax (reported) |
|
|
7,126 |
9,512 |
10,374 |
11,122 |
11,623 |
Reported tax |
(870) |
(959) |
(1,245) |
(1,501) |
(1,743) |
||
Profit After Tax (norm) |
6,793 |
8,553 |
9,129 |
9,620 |
9,880 |
||
Profit After Tax (reported) |
6,256 |
8,553 |
9,129 |
9,620 |
9,880 |
||
Minority interests |
0 |
0 |
0 |
0 |
0 |
||
Discontinued operations |
0 |
0 |
0 |
0 |
0 |
||
Net income (normalised) |
6,900 |
8,553 |
9,129 |
9,620 |
9,880 |
||
Net income (reported) |
6,256 |
8,553 |
9,129 |
9,620 |
9,880 |
||
Basic average number of shares outstanding (m) |
53.2 |
55.4 |
56.0 |
56.0 |
56.0 |
||
EPS - basic normalised (p) |
|
|
13.0 |
15.4 |
16.3 |
17.2 |
17.6 |
EPS - normalised (p) |
|
|
11.8 |
14.8 |
15.9 |
16.8 |
17.2 |
EPS - basic reported (p) |
|
|
11.8 |
15.4 |
16.3 |
17.2 |
17.6 |
Dividend per share (p) |
2.0 |
2.7 |
3.0 |
3.3 |
3.7 |
||
Revenue growth (%) |
13.1 |
21.6 |
12.9 |
7.2 |
7.5 |
||
Gross Margin (%) |
38.4 |
39.9 |
41.6 |
41.6 |
41.7 |
||
EBITDA Margin (%) |
18.9 |
19.8 |
19.5 |
19.2 |
18.9 |
||
Normalised Operating Margin |
14.1 |
14.3 |
14.3 |
13.9 |
13.5 |
||
BALANCE SHEET |
13,748 |
13,717 |
16,687 |
18,820 |
|||
Fixed Assets |
|
|
6,367 |
6,332 |
6,897 |
8,395 |
9,948 |
Intangible Assets |
4,792 |
4,963 |
5,701 |
7,371 |
9,073 |
||
Tangible Assets |
1,575 |
1,369 |
1,196 |
1,024 |
875 |
||
Investments & other |
0 |
0 |
0 |
0 |
0 |
||
Current Assets |
|
|
28,191 |
36,126 |
43,313 |
50,341 |
56,802 |
Stocks |
11,361 |
9,000 |
8,939 |
10,728 |
11,650 |
||
Debtors |
11,224 |
12,952 |
14,005 |
16,102 |
17,781 |
||
Cash & cash equivalents |
5,606 |
14,174 |
20,369 |
23,510 |
27,371 |
||
Other |
0 |
0 |
0 |
0 |
0 |
||
Current Liabilities |
|
|
(9,256) |
(8,663) |
(9,686) |
(10,697) |
(11,254) |
Creditors |
(8,612) |
(8,204) |
(9,227) |
(10,143) |
(10,611) |
||
Tax and social security |
(644) |
(459) |
(459) |
(554) |
(643) |
||
Short term borrowings |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
0 |
||
Long Term Liabilities |
|
|
(282) |
(245) |
(285) |
(375) |
(467) |
Long term borrowings |
0 |
0 |
0 |
0 |
0 |
||
Other long term liabilities |
(282) |
(245) |
(285) |
(375) |
(467) |
||
Net Assets |
|
|
25,020 |
33,550 |
40,239 |
47,664 |
55,029 |
Minority interests |
0 |
0 |
0 |
0 |
0 |
||
Shareholders' equity |
|
|
25,020 |
33,550 |
40,239 |
47,664 |
55,029 |
CASH FLOW |
|||||||
Op Cash Flow before WC and tax |
10,249 |
13,109 |
14,563 |
15,360 |
16,239 |
||
Working capital |
(6,009) |
407 |
(635) |
(2,971) |
(2,132) |
||
Exceptional & other |
(417) |
137 |
(0) |
(0) |
(0) |
||
Tax |
(165) |
(633) |
(1,245) |
(1,501) |
(1,743) |
||
Net operating cash flow |
|
|
3,658 |
13,020 |
12,683 |
10,888 |
12,364 |
Capex |
(3,675) |
(3,614) |
(4,535) |
(5,914) |
(6,435) |
||
Acquisitions/disposals |
0 |
0 |
0 |
0 |
0 |
||
Net interest |
(111) |
(42) |
(300) |
50 |
50 |
||
Equity financing |
172 |
258 |
0 |
0 |
0 |
||
Dividends |
(976) |
(1,138) |
(1,653) |
(1,882) |
(2,118) |
||
Other |
365 |
84 |
0 |
0 |
0 |
||
Net Cash Flow |
(567) |
8,568 |
6,195 |
3,141 |
3,860 |
||
Opening net debt/(cash) |
|
|
(6,173) |
(5,606) |
(14,174) |
(20,369) |
(23,510) |
FX |
0 |
0 |
0 |
0 |
0 |
||
Other non-cash movements |
0 |
0 |
0 |
0 |
0 |
||
Closing net debt/(cash) |
|
|
(5,606) |
(14,174) |
(20,369) |
(23,510) |
(27,371) |
Source: Company accounts, Edison Investment Research
|
|
Research: Healthcare
Basilea reported a definable FY17, as a multitude of licensing/distribution agreements announced in 2016/17 for launched anti-infective drug assets Cresemba (isavuconazole) and Zevtera (ceftobiprole) aided reported product sales, royalty and milestone income. Total revenues grew 54% to CHF101.5m, of which CHF16.3m related to product sales and CHF15.0m to royalty income. Operating losses declined by 68% to CHF14.1m. For 2018, we expect operating losses to reduce further as higher R&D costs are offset by growth in total revenues. We value Basilea at CHF1,231m.